The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Future developments in myeloma treatment
Sally Moore, MD, Royal United Hospital, Bath, UK, briefly discusses future developments in multiple myeloma (MM) treatment, drawing focus on the use of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. Dr Moore also mentions the excitement surrounding other novel agents in myeloma treatment, their increasing efficacy, and the improved management of toxicities. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
